Welcome to our dedicated page for NorthView Acquisition news (Ticker: PFSA), a resource for investors and traders seeking the latest updates and insights on NorthView Acquisition stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NorthView Acquisition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NorthView Acquisition's position in the market.
Profusa (Nasdaq: PFSA) announced on October 7, 2025 a second $1 million investment in digital treasury assets as part of its treasury management strategy to hedge macroeconomic uncertainty. The company said the strategy supports commercial and development plans for its Lumee continuous biochemical monitoring platform and aims to maintain capital for AI-driven digital health initiatives. Profusa noted continued collaboration with Ascent Partners Fund, which funded an additional $2 million tranche to establish a low-cost, capital-efficient Bitcoin treasury approach the company views as a digital store of value. Management framed the purchases as a foundation for progressing commercial and clinical programs.
Profusa (NASDAQ:PFSA), a digital health company, has announced a significant collaboration with Dr. Yann Gouëffic, a leading French surgeon specializing in critical limb threatening ischemia (CLTI). Dr. Gouëffic, along with his FRANCE-PAD network, will adopt Profusa's Lumee™ oxygen monitoring technology for both clinical practice and home monitoring studies.
The collaboration is notable as Dr. Gouëffic and his affiliated practices handle approximately 8% of all CLTI cases in France. Dr. Gouëffic brings over 20 years of experience in endovascular procedures and has authored more than 140 peer-reviewed articles. The partnership aims to advance vascular disease management in Europe, where the endovascular market includes over 300,000 procedures annually.
Profusa (NASDAQ:PFSA), a digital health company, has announced the integration of NVIDIA technology to develop an AI-powered insight portal for continuous biochemistry monitoring. The portal will combine Profusa's Lumee™ oxygen monitoring system with NVIDIA NeMo to enable advanced clinical workflows.
The platform will feature an AI-driven physician portal with capabilities including EMR integration, remote monitoring, and a longitudinal health data graph that combines Profusa biomarkers with various health data sources. The system aims to provide real-time biochemistry monitoring and actionable clinical insights for healthcare providers.
Profusa plans to launch the portal in early 2026 across the European Economic Area (EEA) where CE Mark certification is accepted.
Profusa (NASDAQ:PFSA), a digital health company, announces a new commercial and clinical collaboration with the Department of Vascular Surgery at AZ Sint Blasius Hospital, Belgium. The partnership is led by Dr. Koen Deloose, an internationally recognized vascular surgeon specializing in critical limb ischemia (CLTI).
Dr. Deloose, who treats over 300 CLTI patients annually, has successfully implemented Profusa's Lumee™ Oxygen measurement system for monitoring endovascular revascularization procedures. The technology provides real-time tissue oxygen perfusion metrics crucial for treatment success. Dr. Deloose's modern vascular clinic offers a multidisciplinary approach, combining expertise from diabetic foot specialists, wound care experts, and podiatrists.
Profusa (NASDAQ: PFSA), a commercial stage digital health company focused on continuous biochemistry monitoring technology, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Ben Hwang, Ph.D., will deliver a corporate overview at the event, which takes place September 8-10, 2025 at the Lotte New York Palace Hotel.
The presentation will be available on demand to registered conference attendees starting September 5, 2025, at 7:00 AM ET. Investors can register for the conference and request one-on-one meetings through the conference website.
Profusa (NASDAQ:PFSA), a digital health company, has announced a significant commercial and clinical collaboration with Prof. Dr. Marianne Brodmann at the Medical University of Graz, Austria. The partnership centers around the adoption of Profusa's Lumee Oxygen platform in Prof. Brodmann's practice, which conducts approximately 1,500 annual vascular procedures.
Prof. Brodmann, who previously served as PI for Lumee Oxygen's CE Mark clinical studies, will integrate the technology into her clinical practice and research programs. The collaboration aims to explore additional indications for Profusa's proprietary technology while providing real-time oxygen perfusion monitoring for patients with critical limb ischemia.
Profusa (NASDAQ: PFSA), a commercial stage digital health company, has announced two significant leadership appointments following its business combination with NorthView Acquisition Corp. Peter O'Rourke, former Acting U.S. Secretary of Veterans Affairs, joins as lead independent director, bringing experience from overseeing 1,300 facilities serving 9 million veterans.
Additionally, Fred Knechtel, a seasoned Fortune 500 financial executive with experience at Northrop Grumman, Stanley Black & Decker, and DuPont, has been appointed as Chief Financial Officer. Both appointments aim to strengthen Profusa's commercialization efforts for its biosensor platform technology focused on continuous monitoring of individual biochemistry.
Profusa (NASDAQ: PFSA), a digital health company, has provided a comprehensive business update following its recent Nasdaq listing on July 14, 2025. The company outlined five strategic pillars: revenue growth, AI infrastructure, clinical/regulatory pathways, financial structure, and operational scale.
Key developments include: $100 million ELOC facility secured for growth funding, planned European launch of Lumee™ platform for tissue oxygen monitoring in Q1 2026, targeting a $10 billion global addressable market. The company aims for U.S. FDA submission mid-2026 with commercialization expected in 2027. Their glucose monitoring platform, addressing a 500 million patient market, is progressing with human validation data expected from EU and APAC clinical sites, targeting commercialization by mid-2027.
Profusa (NASDAQ: PFSA), a digital health company, has signed a Letter of Intent (LOI) for a distribution agreement with Dismeval, S.L. to market its Lumee Oxygen platform in Spain, including the Canary and Balearic Islands.
The partnership marks Profusa's first step in building its European distribution infrastructure. The company targets a $10.5B+ global addressable market for its tissue oxygen technology across three key indications: peripheral artery disease, chronic wounds, and critical limb ischemia. The European market presents significant potential with over 300,000 endovascular procedures annually.
Profusa (NASDAQ: PFSA), a commercial stage digital health company, has announced its initial $1 million investment in Bitcoin (BTC) as part of its digital asset treasury strategy. The company has partnered with BlockFills, a global crypto trading solutions provider, to execute its BTC treasury management strategy.
The investment represents Profusa's strategic move to hedge against macroeconomic uncertainties, reflecting its conviction in Bitcoin as a digital store of value. The company is collaborating with Ascent Partners Fund to establish a cost-efficient Bitcoin treasury strategy while maintaining sufficient capital for its AI-driven digital health platform development.
FAQ
What is the current stock price of NorthView Acquisition (PFSA)?
What is the market cap of NorthView Acquisition (PFSA)?
